Tiziana Advances Alzheimer’s Treatment with FDA Nod

Tiziana Life Sciences (TLSA) has released an update.

Tiziana Life Sciences has received FDA approval to begin administering intranasal foralumab to a patient with moderate Alzheimer’s disease under an Expanded Access IND, with treatment starting as early as July. The company believes that foralumab, as the only fully human anti-CD3 monoclonal antibody, may slow cognitive decline by targeting neuroinflammation, a key factor in Alzheimer’s pathology. This follows previous IND clearances, positioning foralumab as a potentially groundbreaking treatment for various stages of Alzheimer’s disease.

For further insights into TLSA stock, check out TipRanks’ Stock Analysis page.